The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis

Stopped early · Phase 4

Conditions studied: Cardiac Amyloidosis

In brief

The investigators postulate that F-18 florbetapir will show improved detection of cardiac amyloidosis over conventional non-invasive imaging techniques, particularly in early disease.

Key facts

Study ID

NCT03040427

Run by

The Cleveland Clinic

People needed

12

Starts

2017-01-01

Expected to finish

2019-08-21

Last updated by the study team

2021-07-27

Who can join

Age: 18 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with extra-cardiac biopsy-proven AL or ATTR amyloidosis
• Patients with a ratio of affected to unaffected free light chains >5 or free light chain difference of >50

You may not qualify if…

• Echocardiographic evidence of cardiac amyloidosis with septal and posterior wall thickness ≥ 13mm
• Contraindication to florbetapir or its components
• Refusal to participate in the study

Where it is running

• Cleveland Clinic Foundation (Main Campus) — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.